TMD Titan Medical

Titan Medical to Present at Two Investment Conferences in September

Titan Medical to Present at Two Investment Conferences in September

TORONTO, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Titan Medical Inc. (TSX: TMD) (Nasdaq: TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), today announced that David McNally, President and CEO, will present a corporate overview at two upcoming investment conferences, as follows:

20th Annual Rodman & Renshaw Global Investment Conference

Date and Time:  Wednesday, September 5, 2018 at 12:30 p.m. Eastern time

Venue:               St. Regis New York Hotel in New York City

Wells Fargo Securities 2018 Healthcare Conference

Date and Time:  Thursday, September 6, 2018 at 9:10 a.m. Eastern time

Venue:               The Westin Copley Place in Boston

Mr. McNally’s presentation at the 20th Annual Rodman & Renshaw Global Investment Conference will be webcast live and available for replay under the Investors section of the Company’s website at .

About Titan Medical Inc.

Titan Medical Inc. is focused on research and development through to the planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery. The Company is developing the SPORT Surgical System, a single-port robotic surgical system. The SPORT Surgical System is comprised of a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body. Titan intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures.

For more information, please visit the Company’s website at .

Contacts:

LHA Investor Relations

Kim Sutton Golodetz

(212) 838-3777



   or

Bruce Voss

(310) 691-7100

EN
27/08/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Titan Medical

 PRESS RELEASE

Titan Medical to Issue Second Quarter 2022 Financial Results on August...

Titan Medical to Issue Second Quarter 2022 Financial Results on August 11, 2022 Webcast to Follow Announcement TORONTO, July 25, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that the company plans to issue its second quarter 2022 financial results prior to market opening on Thursday, August 11, 2022. In addition, management will host an investor audio webcast at 8:30 a.m. ET to discuss financial results and business developments in the period. Speakers will incl...

 PRESS RELEASE

Titan Medical Announces Appointment of Cary G. Vance as President and ...

Titan Medical Announces Appointment of Cary G. Vance as President and Chief Executive Officer TORONTO, June 30, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that Cary G. Vance has been appointed as the company’s President and CEO effective July 1, 2022. Mr. Vance will succeed Paul Cataford, Titan’s chair of the board of directors, who has served as Interim President and CEO since December 20...

 PRESS RELEASE

Titan Medical Provides Update to Enos Project Timeline

Titan Medical Provides Update to Enos Project Timeline De Novo marketing authorization planned for early 2025 remains unchanged TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that multiple disruptions have resulted in an updated Investigational Device Exemption (IDE) submission timeline for the Enos™ robotic single access surgery system. The company now expects the IDE subm...

 PRESS RELEASE

Titan Medical Announces Agreement with Nissha Medical Technologies

Titan Medical Announces Agreement with Nissha Medical Technologies TORONTO, ON, June 21, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that it has signed an agreement with Nissha Medical Technologies for the manufacture of surgical consumables. These single-use surgical components will be used for verification and validation testing, and pre-clinical and clinical studies of Titan’s Enos™ robo...

 PRESS RELEASE

Titan Medical Achieves all Third Quarter Milestones Related to the Dev...

Titan Medical Achieves all Third Quarter Milestones Related to the Development of the SPORT Surgical System TORONTO, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces that the Company has achieved all of its publicly stated third quarter 2018 development milestones for the SPORT Surgical System, as follows: Completed the improved camera insertio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch